Evidence map›Paper›PMID 30115697›Full record

ArticleCancer research2018

Tailoring Chemotherapy for the African-Centric S47 Variant of TP53.

Thibaut Barnoud, Anna Budina-Kolomets, Subhasree Basu, Julia I-Ju Leu, Madeline Good, Che-Pei Kung, Jingjing Liu, Qin Liu, Jessie Villanueva, Rugang Zhang and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Emerging insights into ethnic-specific TP53 germline variants.Journal of the National Cancer Institute · 2023
    Review
  4. Article
  5. The African-centric P47S Variant ofCancer research communications · 2023
    Article
  6. Review
  7. A RareCancer research · 2020
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Thibaut BarnoudProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania.
Anna Budina-KolometsProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania.
Subhasree BasuProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania.
Julia I-Ju LeuDepartment of Genetics, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Madeline GoodProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania.
Che-Pei KungICCE Institute and Department of Internal Medicine, Division of Molecular Oncology, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri.ORCID 0000-0002-1150-4998
Jingjing LiuProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-9964-580X
Qin LiuProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-9964-580X
Jessie VillanuevaProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-5701-2609
Rugang ZhangGene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania.
Donna L GeorgeDepartment of Genetics, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Maureen E MurphyProgram in Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, Pennsylvania. mmurphy@wistar.org.
The Wistar Institute · USUniversity of Pennsylvania · USWashington University in St. Louis · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1M
TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5M
Transformed Esophageal Epithelial Cells and the Tumor MicroenvironmentP01CA098101 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RUSTGI, ANIL K · 2003 to 2023
$31.7M
ZINC FINGER PROTEINS IN EARLY KIDNEY DEVELOPMENTP01DK049210 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI AHIMA, REXFORD S. · 1995 to 2016
$26.9M
Washington University Institute of Clinical and Translational Sciences (TL1)TL1TR002344 · NCATS · WASHINGTON UNIVERSITY · PI Jay F. Piccirillo · 2017 to 2026
$8.5M
Functional Analysis of p53 Polymorphic Variants - Diversity SupplementR01CA102184 · NCI · WISTAR INSTITUTE · PI Maureen E. Murphy · 2005 to 2026
$7.4M
The ARF Tumor SuppressorR01CA139319 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2010 to 2019
$3.9M
Targeting TERT in MelanomaR01CA215733 · NCI · WISTAR INSTITUTE · PI VILLANUEVA, JESSIE · 2017 to 2021
$2.4M
p53 Variants in Cancer Risk and TherapyR01CA201430 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2016 to 2020
$2.2M
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutanK01CA175269 · NCI · WISTAR INSTITUTE · PI VILLANUEVA, JESSIE · 2013 to 2017
$754k
Purchase of a Seahorse Bioscience XF AnalyzerS10OD023658 · OD · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2017 to 2017
$188k
NCATS NIH HHS TL1 TR002344NCI NIH HHS F32 CA220972NCI NIH HHS K01 CA175269NCI NIH HHS P01 CA098101NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA102184NCI NIH HHS R01 CA139319NCI NIH HHS R01 CA201430NCI NIH HHS R01 CA215733NIDDK NIH HHS P01 DK049210NIDDK NIH HHS P30 DK050306NIH HHS S10 OD023658
6 · The paper itself

Abstract

The tumor suppressor

Indexed as

Polymorphism, Single NucleotideAfricaAllelesAnimalsApoptosisBlack or African AmericanBlack PeopleCell DeathCell Line, TumorCell Transformation, NeoplasticCisplatinDisease ProgressionFibroblastsGenotypeHumansMiceCisplatinTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID30115697
PMCPMC6168343
OpenAlexW2887991616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.